-transparent.png){kind=logo}
Thirty-eight patients with metastatic melanoma were evaluated immunologically prior to chemoimmunotherapy. The assays used included recall antigen skin hypersensitivity; lymphocyte count; nonspecific T, non-T, and K cell lymphocytotoxicity; and T and B cell rosette enumeration. Survival curves were computed for each of four ranges of values of a given immunologic test. The higher ranges of positive skin tests, lymphocyte count, cytotoxicity, and T and B subpopulation numbers were consistently associated with the longer survivals. The differences reached statistical significance for non-T cell cytotoxicity and B and T cell peripheral blood counts. Pretreatment immune reactivity, particularly that involvingg non-T cell function, appears related to length of survival.
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
December 2017,
Melanoma research,
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
August 1997,
European journal of cancer (Oxford, England : 1990),
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
November 1997,
Journal of immunotherapy (Hagerstown, Md. : 1997),
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
February 1994,
Clinical and experimental immunology,
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
February 1979,
European journal of cancer,
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
October 1991,
Seminars in oncology,
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
October 2022,
Acta oncologica (Stockholm, Sweden),
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
September 1994,
Clinical and experimental immunology,
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
June 2015,
British journal of cancer,
N Thatcher, and
M K Palmer, and
R Swindell, and
D Crowther
January 2010,
The oncologist,
